---
title: Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK
version: 1.4
last-updated: 2025-12-14
---

# Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK  
**Protocol 1 – Preferred First-Line rTKA Pathway**

---

## 1. Purpose
Provide a standardized **first-line** opioid-free intraoperative anesthesia (OFIA) pathway for robot-assisted total knee arthroplasty (rTKA) using **adductor canal block (ACB)** and **IPACK**. This protocol optimizes analgesia, minimizes opioid exposure, reduces PONV, preserves quadriceps strength, and supports ERAS goals including **POD 0 ambulation**.

Protocols are **informed by** ERAS updates (2019–2024), ASA/APSF safety guidance (2024), and ASRA/ESRA regional anesthesia principles (2024–2025) but **do not replace** institutional policies or attending anesthesiologist judgment.

> **Educational Use Only – Not a Clinical Guideline**  
> - All doses represent **typical adult ranges** and must be individualized  
> - Pathway selection remains **attending-dependent**  
> - Frail, elderly, OSA, cardiac, or renal/hepatic-impaired patients require tailored dosing  
> - Conservative guardrails are intentional to reduce misuse risk

---

## 2. Preoperative Phase

### 2.1 Patient Assessment
- Standard preanesthetic evaluation  
- Review prior anesthesia records  
- Identify risk factors for PONV, delirium, OSA, frailty  
- Opioid tolerance assessment  
- **Confirm suitability for deep peripheral nerve blocks**  
- **Screen for ketamine caution contexts** (see Section 4.2): frailty/advanced age, hemodynamic instability, tachyarrhythmia risk, catecholamine-depleted physiology, severe psychiatric disease  

#### Anticoagulation & Block Safety (ASRA/ESRA 2024–2025 + Institutional Policy)
For this repository, **ACB/IPACK are treated as deep peripheral blocks** and require **ASRA/ESRA-consistent timing with institutional policy adherence**.

- Anticoagulation and antiplatelet regimen fully reconciled  
- **Last dose timing and renal function documented when relevant**  
- **Block timing verified using current institutional tables aligned with ASRA/ESRA guidance**  
- If not within safe timing window → **do not perform blocks**; proceed with OFIA block-free or alternative pathway  

> **Note:** Anticoagulation timing is **agent-, dose-, renal function-, and procedure-dependent**.  
> Do **not** hard-code timing outside institutional guidance.

---

### 2.2 Preoperative Medications (ERAS-Informed)
- **Acetaminophen 1 g PO** (30–60 min pre-op)  
- **Celecoxib 400 mg PO** (1–2 hours pre-op; meloxicam 15 mg alternative)  
- **Dexamethasone 8–10 mg IV** after IV placement  
- **Scopolamine patch 1.5 mg** for *high PONV risk only*  
- **Avoid routine gabapentinoids** (ASA/APSF safety signal: sedation, delirium, respiratory risk)  
- *Midazolam reserved for block placement anxiolysis (below)*

---

## 3. Regional Blocks (Ultrasound-Guided – Essential for Protocol 1)

### 3.1 Pre-Block Anxiolysis
- **Midazolam 1–2 mg IV**  
  - Use **0.5–1 mg** in elderly/OSA/frail  
  - Avoid oversedation  
  - Consider omitting additional midazolam at induction if adequate anxiolysis already achieved

### 3.2 Adductor Canal Block (ACB)
- **20–30 mL ropivacaine 0.2–0.25%**  
- Subsartorial approach targeting the vastoadductor canal  
- Incremental injection with negative aspiration and visualized spread  

### 3.3 IPACK Block
- **15–20 mL ropivacaine 0.2–0.25%**  
- Ultrasound-guided posterior capsule coverage  
- Incremental injection; avoid intravascular/intraneural spread  

### 3.4 Documentation
- Total ropivacaine dose (mg)  
- Conservative maximum reference: **~3 mg/kg ropivacaine equivalent** (institution-dependent)  
- Block type, laterality, volume, concentration  
- Patient tolerance and block quality  
- Confirmation of quadriceps motor preservation (intent)

### 3.5 Safety
- **Lipid emulsion 20% immediately available**  
- LAST response pathway visible and accessible  
- Standard monitoring during and after block placement

---

## 4. Induction

### 4.1 Primary Induction (Propofol-Based)
- **Propofol 1.5–2 mg/kg IV**  
- **Rocuronium 0.6–1.0 mg/kg IV**  
- **Midazolam 0–0.5 mg IV** *only if needed* (often omit if already dosed for blocks)

### 4.2 Ketamine (Optional Adjunct — Not Default)
- **Ketamine 0.2–0.5 mg/kg IV** (sub-anesthetic; titrate)  
- Favor lower end in elderly/frail or hemodynamically fragile patients  

**Use caution / reduce dose / omit** in:
- Hemodynamic instability or catecholamine-depleted physiology  
- Significant tachyarrhythmia risk  
- Advanced frailty or delirium-prone phenotype  
- Active psychosis or unstable psychiatric disease  

**EEG caveat:** Ketamine increases BIS and alters EEG dynamics. Avoid titrating hypnotics to BIS alone after administration.

### 4.3 Adjunct Initiation (Selection-Dependent)
- **Dexmedetomidine infusion** (no routine loading dose):  
  - Start **0.2–0.4 mcg/kg/hr**  
- **Magnesium sulfate 30–50 mg/kg IV** over 15–20 min  
  - Avoid if **CrCl <30 mL/min**

---

## 5. Maintenance

### 5.1 Primary Maintenance
- **Propofol TIVA 75–150 mcg/kg/min** (**default maintenance backbone**)  
- **Optional sevoflurane ~0.5–1.2 MAC** may be added selectively (hybrid or transition strategy)

### 5.2 Adjuncts (Selection-Dependent)
- **Dexmedetomidine 0.2–0.7 mcg/kg/hr** (lower range in elderly/frail)  
- **Ketamine infusion 0.1–0.2 mg/kg/hr** (optional)  
- Magnesium if selected and appropriate  

### 5.3 Hemodynamic Targets
- **MAP ≥65 mmHg** (individualize)  
- Dex-related bradycardia: reduce/stop infusion;  
  - **Glycopyrrolate 0.2–0.4 mg IV** if symptomatic

### Key Principle
**Zero intraoperative opioids** unless conversion is required for safety.

---

## 6. Emergence
(unchanged; content remains consistent)

---

## 7. Postoperative Phase
(unchanged; PACU rescue logic remains consistent)

---

## 9. References
See: **../../07_References_Evidence_2024.md**